Results of Treatment with Pollen Extract (Cernilton^R N) in Chronic Prostatitis and Prostatodynia

Abstract

We report the results of a prospective study with the pollen extract, Cernilton N, in a dose of 1 tablet tid for 6 months for the treatment of chronic prostatitis syndrome in 90 patients. The factors documented before and after 3 and 6 months' treatment were digital rectal examination (DRE) of the prostate, uroflowmetry, bacterial studies, leucocyte counts in urine and measurement of complement C3/coeruloplasmin in the seminal fluid. The patients were divided into 2 groups: those without associated complicating factors (CFs) (n = 72) and those with complicating factors, i.e. urethral strictures, prostatic calculi, bladder neck sclerosis (n = 18). In the group without CFs, 56 (78%) had a favorable response; 26 (36%) were cured of their symptoms and signs and 30 (42%) improved significantly with an increase in flow rate, a reduction in leukocyturia in the post-prostate massage urine (VB3) and a decrease in complement C3/coeruloplasmin in the ejaculate. In the patients with CFs only 1 patient showed a response. Complicating factors should be considered in patients who fail to respond to treatment within 3 months. Cernilton N was well tolerated by 97% of patients.

Cyclic hydroxamic acid inhibitors of prostate cancer cell growth: Selectivity and structure activity relationships

“…Cernilton, a pollen extract, exhibits clinical effectiveness in the treatment of benign prostatic hyperplasia and chronic prostatis [3,4]. In vitro studies demonstrate that the relevant biological activity of cernilton resides in the water-soluble cernitin T-60 fraction rather than in the hydrophobic fraction, and that the water-soluble fraction selectively inhibits the growth of DU-145 human prostate cancer cells, but does not inhibit MCF-7 human breast cancer cells [5].…”

“…A cyclic hydroxamic acid, 2,4-dihydroxy-2H,1,4-benzoxazin-3(4H)-one (DIBOA, 1), was reported recently to inhibit growth of the DU-145 human prostate cancer cell line [1,2]. DIBOA (1) was isolated from the water-soluble fraction of the pollen extract, cernilton, which has been shown to cause symptomatic improvement in patients with benign prostatic hyperplasia, chronic prostatitis, and prostatodynia [3,4].…”

The effect of oral honey and pollen on postoperative intraabdominal adhesions

“…Pollen and pollen products have been shown to have several beneficial applications for human use. It has been successfully used for the treatment of some cases of benign prostatitis and for oral desensitization of children with pollen allergy (7,25,26).…”

Efficacy of pollen extract in association with group B vitamins for pain relief in chronic prostatitis/chronic pelvic pain syndrome: A survey of urologists' knowledge about its clinical application

“…The product is similar to Cernilton that was used by Rugendorff et al in their study to evaluate the effect of treatment with pollen extract in chronic prostatitis and prostatodynia. In this research, 56 of 90 (78%) treated patients had a favorable response, in particular 26 (36%) recovered from their symptoms and 30 (42%) showed a functional improvement, with an increase in flow rate and a decrease of microbiological and physical infection related markers in urine and ejaculate (1). Another interesting study realized by Kamijo T et al…”